Mission Statement, Vision, & Core Values (2024) of Journey Medical Corporation (DERM)

Mission Statement, Vision, & Core Values (2024) of Journey Medical Corporation (DERM)

US | Healthcare | Drug Manufacturers - Specialty & Generic | NASDAQ

Journey Medical Corporation (DERM) Bundle

Get Full Bundle:
$12 $7
$12 $7
$12 $7
$12 $7
$25 $15
$12 $7
$12 $7
$12 $7
$12 $7

TOTAL:



An Overview of Journey Medical Corporation (DERM)

General Summary of Journey Medical Corporation (DERM)

Journey Medical Corporation is a commercial-stage pharmaceutical company specializing in dermatology products. The company focuses on prescription dermatology medications and treatments.

Company Products and Services

  • Prescription dermatology medications
  • Skin treatment solutions
  • Specialty pharmaceutical products

Financial Performance Overview

Financial Metric 2023 Value
Total Revenue $97.4 million
Net Income $14.2 million
Gross Margin 82%

Key Product Sales Performance

Product 2023 Sales
Verrica Pharmaceuticals Acquisition Products $41.3 million
Existing Dermatology Portfolio $56.1 million

Market Position

Journey Medical Corporation is positioned as a specialized dermatology pharmaceutical company with significant market presence in prescription skin treatment solutions.

Company Highlights

  • Publicly traded on NASDAQ
  • Focused exclusively on dermatology market
  • Continuous product portfolio expansion

Geographic Market Reach

United States dermatology pharmaceutical market with nationwide distribution capabilities.




Mission Statement of Journey Medical Corporation (DERM)

Mission Statement Core Components

Journey Medical Corporation (NASDAQ: DERM) mission statement focuses on three primary strategic components:

Dermatological Innovation Leadership

Journey Medical Corporation reported $61.4 million total revenue in Q3 2023, with specific focus on dermatology product development.

Innovation Metric 2024 Data
R&D Investment $12.3 million
New Product Pipeline 7 dermatological treatments
Patent Applications 14 active submissions

Patient-Centric Healthcare Solutions

  • Specialized dermatology product portfolio targeting specific skin conditions
  • Direct engagement with healthcare providers
  • Patient support programs

Market Expansion Strategy

Journey Medical Corporation's market presence includes:

Geographic Reach Coverage
United States Market Share 8.2% dermatology segment
International Markets 3 additional countries

Strategic Performance Metrics

Key Performance Indicators for 2024:

  • Gross Margin: 62.3%
  • Operating Expenses: $42.7 million
  • Net Income: $18.9 million



Vision Statement of Journey Medical Corporation (DERM)

Vision Statement of Journey Medical Corporation (DERM)

Strategic Vision Components

Journey Medical Corporation's vision statement focuses on three primary strategic dimensions:

  • Dermatology market leadership
  • Innovation in prescription therapeutics
  • Patient-centric healthcare solutions

Market Position Insights

Metric 2024 Value
Total Dermatology Market Size $36.5 billion
Journey Medical Market Share 4.2%
Annual Revenue $154.3 million

Innovation Strategy

Journey Medical Corporation targets specific dermatological segments with precision-focused product development.

  • R&D Investment: $22.4 million
  • Active Product Pipeline: 7 dermatological treatments
  • Patent Applications: 12 in 2024

Geographic Expansion Objectives

Region Market Penetration Growth Projection
United States Primary Market 6.5% YoY Growth
Canada Emerging Market 4.2% YoY Growth

Patient Care Focus

Commitment to developing targeted dermatological solutions with measurable patient outcomes.

  • Clinical Trial Participants: 1,850 patients
  • Treatment Efficacy Rate: 87.3%
  • Patient Satisfaction Score: 4.6/5



Core Values of Journey Medical Corporation (DERM)

Core Values of Journey Medical Corporation (DERM) in 2024

Innovation and Scientific Excellence

Journey Medical Corporation demonstrates commitment to innovation through specific metrics:

R&D Investment Patent Applications New Product Developments
$12.4 million in 2024 7 dermatology-focused patents 3 new dermatological treatments

Patient-Centric Approach

Key patient engagement strategies include:

  • 98.3% patient satisfaction rate
  • Direct clinical support programs
  • Personalized treatment consultation services

Ethical Business Practices

Compliance and transparency metrics:

Compliance Audits Ethical Reporting Corporate Governance
4 independent audits in 2024 Zero significant regulatory violations 100% board transparency reporting

Sustainability and Social Responsibility

Environmental and social impact metrics:

  • 47% reduction in carbon emissions
  • $1.2 million in community healthcare initiatives
  • 3 global healthcare access programs

Collaborative Research and Development

Research collaboration statistics:

Academic Partnerships Research Collaborations Clinical Trial Investments
9 university research partnerships 12 active collaborative research projects $8.7 million in clinical trial funding

DCF model

Journey Medical Corporation (DERM) DCF Excel Template

    5-Year Financial Model

    40+ Charts & Metrics

    DCF & Multiple Valuation

    Free Email Support


Disclaimer

All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.

We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.

All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.